| 12/16/2024 15:30 |
Announcement on Acquisition and Cancellation of Stock Options (Share Acquisition Rights) |
| 12/16/2024 15:30 |
Notice Concerning Recording of Non-operating Income, Extraordinary Gains, and Deferred Income Taxes |
| 12/16/2024 15:30 |
Consolidated Financial Results for the Nine Months Ended October 31, 2024 [Japanese GAAP] |
| 12/06/2024 15:30 |
The Yield Results of the Second Commercial Production Run for AKUUGO(R) |
| 10/30/2024 15:00 |
Notice Concerning the Grant of New Patent for Cell Therapy Using SB623 for Chronic Ischemic Stroke in the United States |
| 09/18/2024 15:00 |
Presentation for Financial Results for the 2nd Quarter of the Fiscal Year Ending January 31, 2025 |
| 09/17/2024 15:00 |
Notice Concerning Recording of Non-operating Income and Deferred Income Taxes |
| 09/05/2024 16:30 |
Positive Results of SB623 for Chronic Effects of TBI, including Sustained Motor Function Improvement up to 48 weeks, published in Neurology |
| 07/29/2024 15:00 |
[Delayed] Notice Concerning Notice of Allowance of New Patent for Cell Therapy Using SB623 for Chronic Ischemic Stroke in the US |
| 07/10/2024 10:30 |
[Delayed] [Results of Basic Research] Publication of an Article on the Neuronal Activity and Network Formation Promotion of SB623 |
| 06/20/2024 09:30 |
Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan |
| 06/13/2024 15:00 |
Consolidated Financial Results for the Three Months Ended April 30, 2024 [Japanese GAAP] |
| 06/13/2024 15:00 |
Notice Concerning Recording of Non-operating Income and Deferred Income Taxes |
| 06/12/2024 15:00 |
Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan |
| 03/26/2024 16:30 |
[Delayed] Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic |
| 03/19/2024 15:00 |
Presentation for Financial Results for the Fiscal Year Ending Jan.31, 2024 |
| 03/18/2024 15:00 |
Consolidated Financial Results for the Fiscal Year Ended January 31, 2024 [Japanese GAAP] |
| 03/18/2024 15:00 |
Announcement on Reduction in Amounts of Stated Capital and Capital Reserves and Appropriation of Other Capital Surplus |
| 03/18/2024 15:00 |
Notice Concerning Differences between Consolidated Earnings Forecast and Actual Results for the Fiscal Year Ending January 31, 2024 |
| 03/18/2024 15:00 |
Notice Concerning Recording of Non-operating Income, Extraordinary Gains, and Deferred Income Taxes |
| 03/18/2024 14:30 |
Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic |
| 02/13/2024 15:00 |
[Delayed] Progress on Disclosed Matters: Completion of Liquidation of Overseas Subsidiary |
| 01/25/2024 18:00 |
Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan |
| 01/09/2024 15:00 |
Announcement on Acquisition and Cancellation of Stock Options (Share Acquisition Rights) |
